John Edward Repine
Physician at Cherry Hl Farm Dr, Englewood, CO

6497877, Dec 24, 2002

Oct 22, 1999

09/355522

Kathleen A. Stringer - Denver CO
Brooks M. Hybertson - Boulder CO
John E. Repine - Englewood CO
Joe M. McCord - Denver CO

University Technology Corporation - Boulder CO

A61K 3848

424 9464, 424 9463, 435212, 435226, 514 2, 514826, 514851, 514886, 514887

Plasminogen activator acts as an anti-inflammatory agent by inhibiting generation of superoxide anion by a mechanism that is not related to L-arginine, is not dependent on thrombolytic activity, and is not a function of oxygen free radical scavenging. Moreover, in in vivo models of inflammation, treatment with plasminogen activator reduces edema without inhibiting neutrophil infiltration in in vivo models of inflammation.

6802812, Oct 12, 2004

Jul 27, 2001

09/917414

Stephen D. Walker - Boulder CO
John E. Repine - Englewood CO
Charles W. Henry - Denver CO
Peter E. Nelson - Longmont CO
R. Dale Zellers - Lafayette CO

Nostix LLC - Boulder CO

A61B 500

600309, 600323

An optical sensor includes an optical source capable of being positioned on a tissue and emitting near infrared light into the tissue at a plurality of selected wavelengths, and a photodetector capable of detecting reflected light from the tissue. The photodetector being positioned on the tissue removed from the optical source but sufficiently close in proximity to the optical source to contact the same general tissue. The optical sensor further includes an oscillator coupled to the optical source and capable of activating the optical source to emit the near infrared light, and a modulator coupled to the oscillator and capable of controlling radio frequency modulation of the optical source to emit a radio frequency component that is used to measure the optical path length and absorbance of an analyte of interest within the tissue.

5389522, Feb 14, 1995

Mar 19, 1993

8/034935

John E. Repine - Englewood CO
Jonathan A. Leff - Littleton CO

C12Q 126, C12Q 130, G01N 3353

435 74

At the initial diagnosis of sepsis (6-24 h before the development of ARDS), serum manganese superoxide dismutase (MnSOD) levels and catalase activities are increased in septic patients who subsequently developed ARDS compared to septic patients who did not develop ARDS. Increases in MnSOD and catalase may be used to predict the occurrence of ARDS in septic patients with the same sensitivity, specificity and efficiency as parallel assessments of serum lactate dehydrogenase (LDH) and Factor VIII levels. Evaluation of serum MnSOD and catalase as well as these other accessible markers facilitates identification of subsets of patients and allows prospective treatment of septic patients who are destined to develop ARDS.

5596011, Jan 21, 1997

Apr 6, 1995

8/418645

Karen M. Repine - Englewood CO
John E. Repine - Englewood CO

A61K 31425, A61K 31195, A61K 3113

514369

Macular degeneration is an age-related eye disease for which there is no known treatment to date that has been shown to be effective at treating or preventing the onset or progression of the disease. Current treatment of non-exudative (dry form) macular degeneration is limited to early diagnosis and careful followup, while symptomatic treatment of exudative (wet form) macular degeneration includes laser photocoagulation therapy, surgery, low dose radiation (teletherapy), and anti-oxidant or anti-inflammatory therapies. The present invention relates to a new method for treating or preventing the onset or progression of macular degeneration, comprising periodic administration of a glutathione (GSH) enhancing agent alone or in conjunction with at least one of an anti-oxidant or an anti-inflammatory therapy, and possibly in addition to one or more of the symptomatic treatments mentioned above.

2003002, Feb 6, 2003

Jun 13, 2002

10/172364

John Repine - Englewood CO, US

C12Q001/26, A61K031/00

514/001000, 435/025000

Oxidative stress and inflammation often occur in the eye and often in association with aging or ocular disease. Increases in blood oxidative stress and inflammatory factors can be used to identify individuals with increased ocular oxidative stress and inflammation, select and guide appropriate interventions or treatments, identify selected patients for clinical study and/or determine the efficacy of various interventions or treatments. The present invention describes such factors and will improve the diagnosis, treatment and prevention of ocular oxidative stress and/or inflammation and related ocular conditions.

5639629, Jun 17, 1997

Nov 30, 1994

8/347290

John E. Repine - Englewood CO
Jonathan A. Leff - Littleton CO

The Regents of the University of Colorado - Boulder CO
The Webb-Waring Institute for Biomedical Research - Denver CO

C12Q 132, C12Q 130

435 26

At the initial diagnosis of sepsis (6-24 h before the development of ARDS), serum lactate dehydrogenase (LDH) activity level is increased in septic patients who subsequently develop ARDS compared to healthy patients and septic patients who do not develop ARDS. A method is disclosed for predicting the occurrence of ARDS in a septic patient from the patient's serum level of LDH activity, which method facilitates identification of subsets of patients destined to develop ARDS and allows prospective treatment of such septic patients.

2008000, Jan 3, 2008

Jun 30, 2006

11/428217

Stephen D. Walker - Boulder CO, US
Peter E. Nelson - Longmont CO, US
R. Dale Zellers - Lafayette CO, US
Charles W. Henry - Denver CO, US
John E. Repine - Englewood CO, US

A61B 5/00

600310, 600344, 600316, 600323

In a tissue sensor, a plurality of emitters are configured to emit narrowband light into biological tissue at a plurality of selected wavelengths including one or more wavelengths indicative of a profile for one or more selected analytes and a reference wavelength at which absorbance for the selected analyte is negligible. The sensor further comprises a photo detector configured to detect light at wavelengths that emerge from the biological tissue.

5679532, Oct 21, 1997

Dec 13, 1995

8/571588

John E. Repine - Englewood CO

University Technology Corporation - Boulder CO

G01N 3353, G01N 33573, C12Q 132, C12Q 130

435 71

The invention relates to the discovery that serum ferritin concentrations are elevated in patients at risk for the development of Acute Respiratory Distress Syndrome (ARDS) and who subsequently develop ARDS, as compared to at-risk patients who do not subsequently develop ARDS. Thus, the invention includes a method for determining ARDS development potential in an at-risk patient comprising the steps of determining the patient's serum concentration of ferritin and determining ARDS development potential from said serum concentration of ferritin.

2003011, Jun 19, 2003

Dec 24, 2002

10/327476

Derrick Katyama - Denver CO, US
Mark Manning - Denver CO, US
Kathleen Stringer - Denver CO, US
John Repine - Englewood CO, US

University Technology Corporation

A61L009/04, A61K038/48

424/045000, 514/002000

Formulations for pulmonary delivery that include a protein and a non-physiological surfactant at or above the CMC of the surfactant, and methods for preparing and using the same.

7251516, Jul 31, 2007

May 11, 2004

10/844230

Stephen D. Walker - Boulder CO, US
Peter E. Nelson - Longmont CO, US
R. Dale Zellers - Lafayette CO, US
Charles W. Henry - Denver CO, US
John E. Repine - Englewood CO, US

Nostix LLC - Boulder CO

A61B 5/00

600316

Glucose concentration is noninvasively measured by measuring a plurality of absorption values using at least one emitter operating at a corresponding plurality of emission wavelengths through a common optical sample volume and deriving glucose concentration from the absorption measurement values.